stock upgrade
Wolfe Research Upgrades Danaher to Outperform
The upgrade is based on the firm's improving growth, more reasonable valuations, and its ability to deploy capital.
Barclays Upgrades Revvity to Overweight
The firm's analysts wrote that they see stability in Revvity's diagnostics business and growth above peers in its life sciences and reagents business.
Craig-Hallum Upgrades QuidelOrtho to Buy
The investment bank said the company's core growth should accelerate as QuidelOrtho continues to penetrate the immunoassay market and expand its menu.
Craig-Hallum Upgrades CareDx to Buy
Analyst Bill Bonello said CareDx has substantially de-risked its business and could benefit from Medicare coverage of kidney transplant surveillance testing.
Cowen Upgrades PerkinElmer Stock to Outperform
Analyst Max Masucci said the firm is expected to generate at least $3.21 billion in COVID-19-related revenues, while he lowered the stock price target to $164 per share.
Dec 22, 2020
Illumina Upgraded to Overweight by Piper Sandler
Jan 4, 2019
Cowen Upgrades Myriad Genetics Stock
Jun 1, 2018
Leerink Upgrades T2 Biosystems to To Outperform
Mar 8, 2018
Raymond James Upgrades Quidel to Strong Buy
Dec 11, 2017
Cowen Upgrades Hologic to Outperform
Apr 21, 2017
Raymond James Upgrades Quest to Outperform
Mar 7, 2017
Janney Upgrades Foundation Medicine to Neutral
Sep 19, 2016